Your Health, We Care
Release date: 2026-01-20 17:57:25 Recommended: 18
Ponatinib is an oral tyrosine kinase inhibitor primarily indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in patients who are resistant or intolerant to prior therapies. It is particularly effective in patients harboring the T315I mutation.
Its core mechanism of action lies in inhibiting the activity of the abnormal BCR-ABL protein, thereby blocking the growth of cancer cells. Common adverse effects include hypertension, skin rash, and abdominal pain. In severe cases, it may cause thrombosis, cardiovascular events, or pancreatitis, and thus must be administered strictly in accordance with the physician’s instructions.
Targeted inhibition of BCR-ABL protein: Ponatinib suppresses the proliferation and survival of leukemia cells by blocking the activity of the BCR-ABL protein, including its T315I mutant form.
For the treatment of chronic-phase, accelerated-phase, or blast-phase CML patients who have failed prior therapies (e.g., resistant to imatinib, dasatinib, etc.).
For relapsed or refractory Ph+ALL patients.
For CML or Ph+ALL patients harboring the T315I mutation (one of the only drugs targeting this specific mutation).
Studies have demonstrated a relatively high response rate in patients with drug resistance or mutations, but the efficacy should be evaluated based on the individual patient’s condition.
Hypertension (requiring regular blood pressure monitoring).
Skin rash, dry skin, or pruritus.
Headache, arthralgia, abdominal pain, constipation, or diarrhea.
Fatigue, fever.
Arterial thrombosis (e.g., myocardial infarction, stroke), which has a relatively high incidence and can be fatal.
Venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism).
Heart failure, arrhythmia.
Pancreatitis, hepatotoxicity, or abnormal liver function.
Increased risk of bleeding (e.g., gastrointestinal bleeding).
